CAGE Bio

CAGE Bio is a private, clinical-stage biotech founded in 2017 and based in Cambridge, Massachusetts. The company's core innovation is a deep eutectic ionic liquid (IL) platform designed to dramatically enhance skin permeation for a wide range of drug modalities, from small molecules to proteins and nucleic acids. This technology underpins a pipeline of localized therapies intended to treat serious skin conditions with high efficacy and improved safety profiles. The company is led by a seasoned team with extensive drug development and commercialization experience and has initiated its first clinical trial for vitiligo.

Proprietary deep eutectic ionic liquid (IL) platform designed to enhance skin permeation for a wide range of drug modalities, including small molecules, proteins, and nucleic acids, by interacting with skin lipids at a molecular scale.

CAGE Bio competes with other companies developing topical formulations for immunodermatology, including those using traditional enhancers, nanoparticles, and physical methods like microneedles. It also faces competition from systemic and topical JAK inhibitors and biologics already on the market or in development for conditions like vitiligo and psoriasis.